Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives

BACKGROUND: Axitinib is a next-generation, selective tyrosine kinase inhibitor targeting the vascular endothelial growth factor receptors. It is approved for the treatment of metastatic renal cell carcinoma (mRCC) based on a demonstrated progression-free survival advantage over sorafenib in the seco...

Descripción completa

Detalles Bibliográficos
Autores principales: Narayan, Vivek, Haas, Naomi Balzer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4822864/
https://www.ncbi.nlm.nih.gov/pubmed/27099525
http://dx.doi.org/10.2147/IJNRD.S83874

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4822864/
https://www.ncbi.nlm.nih.gov/pubmed/27099525
http://dx.doi.org/10.2147/IJNRD.S83874

Ejemplares similares